AR047747A1 - Moduladores de furosemida de hm74 - Google Patents
Moduladores de furosemida de hm74Info
- Publication number
- AR047747A1 AR047747A1 ARP050100596A ARP050100596A AR047747A1 AR 047747 A1 AR047747 A1 AR 047747A1 AR P050100596 A ARP050100596 A AR P050100596A AR P050100596 A ARP050100596 A AR P050100596A AR 047747 A1 AR047747 A1 AR 047747A1
- Authority
- AR
- Argentina
- Prior art keywords
- contain
- substituted
- combinations
- heteroatom
- branched
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Reivindicacion 1: Un método terapéutico para modular la actividad senalizadora de HM74 o la transduccion de senales, en un paciente que necesite tratamiento, que comprende administrar a dicho paciente una molécula que tiene la estructura (1) en la que R es H, o alquilo C1-18, que puede ser ramificado, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; alquenilo C1-18, que puede estar ramificado, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; un alquinilo C1-18, que puede estar ramificado, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; un arilo C3-18 que puede contener un grupo lateral, puede contener un puente, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; o un cicloalquilo C5-18, que puede contener un grupo lateral, puede contener un puente, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; Q y X son cada uno O, S o NR; Y es alquilo C1-18, que puede estar ramificado, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; alquenilo C1-18, que puede estar ramificado, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; un alquinilo C1-18, que puede estar ramificado, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; un arilo C3-18 que puede contener un grupo lateral, puede contener un puente, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; o un cicloalquilo C5-18, que puede contener un grupo lateral, puede contener un puente, puede contener un heteroátomo o puede estar sustituido, o sus combinaciones; o sus combinaciones, en las que X e Y pueden estar fusionados dentro de uno o más anillos cuando X es N, en el que dicho anillo es un heterociclo C3-18, que puede estar ramificado y que puede contener un grupo lateral, un heteroarilo C3-18 que puede estar ramificado y que puede contener un grupo lateral, un cicloalquilo C3-18 sustituido, que puede estar ramificado y que puede contener un grupo lateral, o arilo C3-18, que puede estar ramificado y que puede contener un grupo lateral; y cada Z es R.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54601104P | 2004-02-20 | 2004-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047747A1 true AR047747A1 (es) | 2006-02-15 |
Family
ID=34910746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100596A AR047747A1 (es) | 2004-02-20 | 2005-02-18 | Moduladores de furosemida de hm74 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7232811B2 (es) |
| EP (1) | EP1718292A1 (es) |
| JP (1) | JP2007523166A (es) |
| KR (1) | KR20060127141A (es) |
| CN (1) | CN1921845A (es) |
| AR (1) | AR047747A1 (es) |
| AU (1) | AU2005216879B2 (es) |
| BR (1) | BRPI0506792A (es) |
| CA (1) | CA2557444A1 (es) |
| CR (1) | CR8528A (es) |
| EC (1) | ECSP066777A (es) |
| IL (1) | IL177086A (es) |
| MA (1) | MA28373A1 (es) |
| ME (1) | MEP21108A (es) |
| MX (1) | MXPA06008612A (es) |
| NO (1) | NO20064237L (es) |
| NZ (1) | NZ548830A (es) |
| RS (1) | RS20060473A (es) |
| RU (1) | RU2006133540A (es) |
| SG (1) | SG164305A1 (es) |
| TN (1) | TNSN06234A1 (es) |
| TW (1) | TW200538109A (es) |
| WO (1) | WO2005082350A1 (es) |
| ZA (1) | ZA200606679B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| AU2005311930B9 (en) | 2004-12-03 | 2009-09-10 | Merck Sharp & Dohme Corp. | Substituted piperazines as CB1 antagonists |
| CA2635261A1 (en) * | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| KR20080097426A (ko) * | 2006-01-18 | 2008-11-05 | 쉐링 코포레이션 | 칸나비노이드 수용체 조절제 |
| WO2008052190A2 (en) * | 2006-10-26 | 2008-05-02 | Flynn Gary A | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| LT6401B (lt) * | 2015-07-28 | 2017-06-12 | Vilniaus Universitetas | Karboanhidrazės selektyvūs inhibitoriai |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875150A (en) | 1969-04-29 | 1975-04-01 | Leo Pharm Prod Ltd | New sulfamyl-anthranilic acids |
| GB1260155A (en) * | 1969-04-29 | 1972-01-12 | Leo Pharm Prod Ltd | Sulphonamido anthranilic acid derivatives |
| DE2206424A1 (de) * | 1971-02-15 | 1972-08-24 | Dumex Ltd As | Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten |
| DE2247828A1 (de) * | 1972-09-29 | 1974-04-04 | Hoechst Ag | Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung |
| DE2406972C3 (de) * | 1974-02-14 | 1979-07-19 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren |
| DE2718871C3 (de) * | 1977-04-28 | 1980-07-17 | Hoechst Ag, 6000 Frankfurt | N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck |
| US4406896A (en) * | 1979-12-20 | 1983-09-27 | Merck & Co., Inc. | Adjuvants for rectal delivery of drug substances |
| DE3006686A1 (de) * | 1980-02-22 | 1981-08-27 | Hoechst Ag, 6000 Frankfurt | 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3041812A1 (de) * | 1980-11-06 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3101960A1 (de) * | 1981-01-22 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung" |
| US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
| JPH0720862B2 (ja) * | 1989-01-27 | 1995-03-08 | ヘキスト・アクチエンゲゼルシヤフト | 吸入用喘息治療剤 |
| EP1007563A4 (en) * | 1997-06-12 | 2003-04-16 | Smithkline Beecham Corp | HM74A RECEPTOR |
| GB0021484D0 (en) * | 2000-09-01 | 2000-10-18 | Boehringer Ingelheim Pharma | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20030109673A1 (en) * | 2002-10-04 | 2003-06-12 | Xiao Yonghong | Regulation of human hm74-like g protein coupled receptor |
-
2005
- 2005-02-10 KR KR1020067016657A patent/KR20060127141A/ko not_active Application Discontinuation
- 2005-02-10 ME MEP-211/08A patent/MEP21108A/xx unknown
- 2005-02-10 RU RU2006133540/04A patent/RU2006133540A/ru not_active Application Discontinuation
- 2005-02-10 AU AU2005216879A patent/AU2005216879B2/en not_active Ceased
- 2005-02-10 RS RSP-2006/0473A patent/RS20060473A/sr unknown
- 2005-02-10 SG SG200901539-7A patent/SG164305A1/en unknown
- 2005-02-10 JP JP2006554129A patent/JP2007523166A/ja active Pending
- 2005-02-10 WO PCT/US2005/004108 patent/WO2005082350A1/en not_active Application Discontinuation
- 2005-02-10 MX MXPA06008612A patent/MXPA06008612A/es active IP Right Grant
- 2005-02-10 CN CNA2005800054570A patent/CN1921845A/zh active Pending
- 2005-02-10 BR BRPI0506792-8A patent/BRPI0506792A/pt not_active IP Right Cessation
- 2005-02-10 NZ NZ548830A patent/NZ548830A/en unknown
- 2005-02-10 EP EP05713210A patent/EP1718292A1/en not_active Withdrawn
- 2005-02-10 CA CA002557444A patent/CA2557444A1/en not_active Abandoned
- 2005-02-14 US US11/057,587 patent/US7232811B2/en not_active Expired - Fee Related
- 2005-02-18 TW TW094104731A patent/TW200538109A/zh unknown
- 2005-02-18 AR ARP050100596A patent/AR047747A1/es not_active Application Discontinuation
-
2006
- 2006-07-24 CR CR8528A patent/CR8528A/es not_active Application Discontinuation
- 2006-07-25 IL IL177086A patent/IL177086A/en not_active IP Right Cessation
- 2006-07-28 TN TNP2006000234A patent/TNSN06234A1/en unknown
- 2006-08-11 ZA ZA200606679A patent/ZA200606679B/xx unknown
- 2006-08-18 EC EC2006006777A patent/ECSP066777A/es unknown
- 2006-08-29 MA MA29295A patent/MA28373A1/fr unknown
- 2006-09-19 NO NO20064237A patent/NO20064237L/no not_active Application Discontinuation
-
2007
- 2007-05-07 US US11/745,131 patent/US7556931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0506792A (pt) | 2007-05-22 |
| WO2005082350A8 (en) | 2005-12-08 |
| ECSP066777A (es) | 2006-11-16 |
| SG164305A1 (en) | 2010-09-29 |
| NO20064237L (no) | 2006-09-19 |
| IL177086A (en) | 2010-06-16 |
| IL177086A0 (en) | 2006-12-10 |
| MXPA06008612A (es) | 2007-01-25 |
| US20070213391A1 (en) | 2007-09-13 |
| AU2005216879A1 (en) | 2005-09-09 |
| ZA200606679B (en) | 2008-01-30 |
| US7556931B2 (en) | 2009-07-07 |
| CR8528A (es) | 2007-06-08 |
| AU2005216879B2 (en) | 2009-12-10 |
| NZ548830A (en) | 2010-03-26 |
| RU2006133540A (ru) | 2008-03-27 |
| KR20060127141A (ko) | 2006-12-11 |
| US20050187280A1 (en) | 2005-08-25 |
| JP2007523166A (ja) | 2007-08-16 |
| US7232811B2 (en) | 2007-06-19 |
| TNSN06234A1 (en) | 2007-12-03 |
| RS20060473A (en) | 2008-08-07 |
| TW200538109A (en) | 2005-12-01 |
| CN1921845A (zh) | 2007-02-28 |
| MEP21108A (en) | 2010-06-10 |
| CA2557444A1 (en) | 2005-09-09 |
| EP1718292A1 (en) | 2006-11-08 |
| MA28373A1 (fr) | 2006-12-01 |
| WO2005082350A1 (en) | 2005-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047747A1 (es) | Moduladores de furosemida de hm74 | |
| BRPI0414541B8 (pt) | compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários | |
| PE20060500A1 (es) | Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes | |
| CO5550436A2 (es) | Derivados de benzamida | |
| AR037736A1 (es) | Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r) | |
| DE602006020775D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| NI200600306A (es) | Derivados de sulfamida y sulfamato para el tratamiento de la epilepsia y trastornos relacionados | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| DE3879292T2 (de) | Substituierte aromatische sulfonamide als mittel gegen glaukom. | |
| BR0114657A (pt) | Compostos de benzamida e seu uso | |
| AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20041068A1 (es) | Compuestos ciclicos como inhibidores de la proteina tirosina cinasa | |
| AR056883A1 (es) | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 | |
| AR058403A1 (es) | PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. | |
| AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
| AR060405A1 (es) | Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c | |
| EA200602092A1 (ru) | Способ и композиция для лечения ринита | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| ES2037752T3 (es) | Utilizacion de un derivado de benzoxazol y su procedimiento de preparacion. | |
| PE20141280A1 (es) | Inhibidores de aplicacion viral | |
| UY28122A1 (es) | Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| AR042273A1 (es) | Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |